Anti-PDL1 antibody preparationThe present invention provides a stable aqueous pharmaceutical formulation comprising an anti-PDL1 antibody. The present invention also provides methods for making such formulations and methods of using such formulations.Selection drawing Noneヤン, イン...
抗体名:Anti PDL1 mouse monoclonal antibody 浓度:1mg/ml % 宿主:Mouse 用途:科研实验 应用范围:Elisa,WB,flow,IHC 产地:中国 品牌:chemstan 货号:CS10056Mo 用途:科研实验 保质期:一年 包装规格:100ul 保存条件:Stable for one year at -20°C
Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets Xuanbo Da Bangping Cao Yulong Yang BMC Cancer(2024) Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies ...
交叉反应: Human Mouse 克隆类型: Polyclonal Antibody 免疫原: Recombinant protein of human SPDL1 品牌: solarbio 宿主: Rabbit 稀释比例: WB 1:500-2000. 性状: 液体 亚型: IgG 应用: WB 英文名称: Anti-SPDL1 Polyclonal Antibody 背景资料 Required for the localization of dynein and dynactin to the ...
Here we study the combination of Socazolimab, an anti-PDL1 antibody, carboplatin and etoposide to treat extensive stage small cell lung cancer.Methods:The study is a randomized, double-blinded, placebo-controlled multicenter Phase III clinical trial. Patients who have extensive-stage SCLC are ...
, stably transduced cells were sorted based on expression of mCherry. HLA-A2+MDA-MB-468 cells were generated similar to the above described Luc2 transduction but instead using the pMP71-HLA-0201-His vector (Addgene, 108214). Sorting was based on binding of the anti-HLA-A2 antibody....
An exemplary fusion protein complex comprises an anti-PD-L1 antibody covalently linked to an IL-15N72D and/or an IL-15RαSu/Fc fusion protein. In other aspects, a cytokine receptor, e.g. TGFβRII, and/or the binding domain are covalently linked to a soluble IL-15 receptor alpha sushi...
抗pdl1抗体及其用途 Antibodies and anti-pd-l1 use本申请涉及抗PDL1抗体或其抗原结合片段,编码其的核酸,其治疗性组合物,以及它们用于增强T细胞的功能以上调细胞介导的免疫应答和用于治疗T细胞功能失调性病症,例如肿瘤免疫,和用于治疗癌症的用途. The present application relates to an anti-PD-L1 antibody or ...
ANTI-PDL1 ANTIBODY FORMULATIONSThe invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
ANTI-PDL1 ANTIBODY FORMULATIONSThe invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.YINGSREEDHARA